Literature DB >> 20412129

Proliferation of myofibroblasts in the stroma of renal oncocytoma.

T-H Yen1, Y Chen, J-F Fu, C-H Weng, Y-C Tian, C-C Hung, J-L Lin, C-W Yang.   

Abstract

OBJECTIVES: Myofibroblasts are a vital component of stroma of many malignant neoplasms, but it is not yet established whether stromal myofibroblasts also exist in benign tumours such as oncocytoma of the kidney.
MATERIALS AND METHODS: Histomorphological and immunohistochemical analysis of 16 renal oncocytomas diagnosed at Chang Gung Memorial Hospital, Taiwan, has been performed.
RESULTS: Renal oncocytomas were composed of oncocytes, large cells with granular eosinophilic cytoplasm, arranged mostly in sheets, in tubulocystic or combined pattern. Few oncocytes appeared to be undergoing proliferation or apoptosis. MIB-1 and active caspase 3 indices were low, but higher in tumour than in surrounding non-tumour parenchyma (MIB-1: 0.93 +/- 0.09 versus 0.46 +/- 0.07, P < 0.001 and active caspase 3: 0.76 +/- 0.08 versus 0.41 +/- 0.09, P < 0.001). Wnt/beta-catenin signalling was not implicated in this neoplasm, as there was no loss of E-cadherin membranous localization or expression of intranuclear beta-catenin in the cells. Clumps of oncocytes were stained with periodic acid Schiff and had collagen I-, collagen III- and fibronectin-positive, but desmin- and human caldesmon-negative stromas. Importantly, alpha-smooth muscle actin (SMA)-immunostaining established the myofibroblastic nature of many of the stromal cells. Some of the myofibroblasts were also positive for MIB-1, indicating a proliferative role for them in the stroma.
CONCLUSIONS: Renal oncocytomas were composed of two independent compartments: benign oncocytes and pronounced fibrotic stroma, which consisted of proliferating myofibroblasts (SMA- and MIB-1-positive) which were associated with excessive deposition of extracellular matrix (periodic acid Schiff-component, collagen I-, collagen III- and fibronectin-positive, and desmin- and human caldesmon-negative).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412129      PMCID: PMC6496508          DOI: 10.1111/j.1365-2184.2010.00681.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  44 in total

1.  Unusual interleukin-4 and -13 signaling in human normal and tumor lung fibroblasts.

Authors:  C Doucet; C Jasmin; B Azzarone
Journal:  Oncogene       Date:  2000-11-30       Impact factor: 9.867

Review 2.  Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations.

Authors:  A P Sappino; W Schürch; G Gabbiani
Journal:  Lab Invest       Date:  1990-08       Impact factor: 5.662

3.  Proximal tubular adenomas of kidney with so-called oncocytic features. A clinicopathologic study of 13 cases of a rarely reported neoplasm.

Authors:  M J Klein; Q J Valensi
Journal:  Cancer       Date:  1976-08       Impact factor: 6.860

4.  CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions.

Authors:  Peter J Barth; Schokufe Ebrahimsade; Annette Ramaswamy; Roland Moll
Journal:  Virchows Arch       Date:  2001-11-22       Impact factor: 4.064

5.  Bone marrow-derived cells contribute to infarct remodelling.

Authors:  Helge Möllmann; Holger M Nef; Sawa Kostin; Christof von Kalle; Ingo Pilz; Michael Weber; Jutta Schaper; Christian W Hamm; Albrecht Elsässer
Journal:  Cardiovasc Res       Date:  2006-06-14       Impact factor: 10.787

6.  The cellular origin and proliferative status of regenerating renal parenchyma after mercuric chloride damage and erythropoietin treatment.

Authors:  T-H Yen; M R Alison; H T Cook; R Jeffery; W R Otto; N A Wright; R Poulsom
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

7.  Desmoplastic breast carcinoma as a source of human myofibroblasts.

Authors:  S H Barsky; W R Green; G R Grotendorst; L A Liotta
Journal:  Am J Pathol       Date:  1984-06       Impact factor: 4.307

8.  Exogenous bone marrow cells do not rescue non-irradiated mice from acute renal tubular damage caused by HgCl2, despite establishment of chimaerism and cell proliferation in bone marrow and spleen.

Authors:  T-C Fang; W R Otto; R Jeffery; T Hunt; M R Alison; H T Cook; N A Wright; R Poulsom
Journal:  Cell Prolif       Date:  2008-08       Impact factor: 6.831

9.  Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.

Authors:  P Kaaijk; G J L Kaspers; E R Van Wering; G J Broekema; A H Loonen; K Hählen; K Schmiegelow; G E Janka-Schaub; G Henze; U Creutzig; A J P Veerman
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

10.  Proliferating cell nuclear antigen expression in non-cycling cells may be induced by growth factors in vivo.

Authors:  P A Hall; P J Coates; R A Goodlad; I R Hart; D P lane
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more
  3 in total

1.  Decreased body fat, elevated plasma transforming growth factor-β levels, and impaired BMP4-like signaling in biglycan-deficient mice.

Authors:  Tao Tang; Joel C Thompson; Patricia G Wilson; Christina Nelson; Kevin Jon Williams; Lisa R Tannock
Journal:  Connect Tissue Res       Date:  2012-08-23       Impact factor: 3.417

2.  APC +/- alters colonic fibroblast proteome in FAP.

Authors:  Bhavinkumar B Patel; Xin-Ming Li; Maketa P Dixon; Elena L Blagoi; Emmanuelle Nicolas; Steven H Seeholzer; David Cheng; Yin A He; Renata A Coudry; Sharon D Howard; Dawn M Riddle; Harry C Cooper; Bruce M Boman; Peggy Conrad; James A Crowell; Alfonso Bellacosa; Alfred Knudson; Anthony T Yeung; Levy Kopelovich
Journal:  Oncotarget       Date:  2011-03

3.  Epidermal growth factor attenuates tubular necrosis following mercuric chloride damage by regeneration of indigenous, not bone marrow-derived cells.

Authors:  Tzung-Hai Yen; Malcolm R Alison; Robert A Goodlad; William R Otto; Rosemary Jeffery; H Terence Cook; Nicholas A Wright; Richard Poulsom
Journal:  J Cell Mol Med       Date:  2014-11-11       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.